Trial Profile
A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin Versus Pitavastatin/Fenofibrate in Complex-dyslipidemia Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Fenofibrate/pitavastatin (Primary) ; Pitavastatin
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- Sponsors Hanlim Pharmaceutical
- 02 Sep 2020 Primary endpoint,The mean percentage change of Non-HDL Cholesterol, has been met as per results published in the Clinical Therapeutics
- 02 Sep 2020 Results published in the Clinical Therapeutics
- 16 Aug 2018 New trial record